Arjun Agarwal Sells 395 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 395 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $16,313.50. Following the completion of the sale, the senior vice president owned 18,863 shares of the company’s stock, valued at $779,041.90. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Oruka Therapeutics Trading Down 1.2%

NASDAQ:ORKA opened at $40.80 on Thursday. The company has a market cap of $2.02 billion, a P/E ratio of -21.94 and a beta of -0.38. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $42.88. The company’s 50-day moving average price is $33.77 and its 200-day moving average price is $28.14.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics during the second quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics in the 2nd quarter worth approximately $31,000. BNP Paribas Financial Markets lifted its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ORKA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Piper Sandler initiated coverage on Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price objective on the stock. Barclays boosted their price objective on Oruka Therapeutics from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, March 13th. Stifel Nicolaus upped their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $60.00 target price on shares of Oruka Therapeutics in a research note on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $59.60.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.